Morepen Laboratories Ltd

Morepen Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Morepen Laboratories Ltd

₹ 73.2 -3.51%
21 Nov 4:00 p.m.
morepen.com BSE: 500288 NSE: MOREPENLAB
About

Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.[1]

Key Points

Leadership in Anti-Asthmatic drug
The company is world leader in Loratadine (140 MT) and has achieved the leadership position of being one of the largest suppliers of anti-asthmatic drug, Montelukast Sodium (85 MT). It is a prominent player in commercial production of drugs Atorvastatin calcium (120 MT), Rosuvastatin calcium of anti-hypercholesterolemic series, Fexofenadine Hydrochloride of antihistamine series, Olmesartan of anti-hypertensive series & their intermediates. [1] [2]

Website BSE NSE
  • Market Cap ₹ 4,012 Cr.
  • Current Price ₹ 73.2
  • High / Low ₹ 101 / 38.6
  • Stock P/E 30.6
  • Book Value ₹ 20.3
  • Dividend Yield 0.00 %
  • ROCE 16.8 %
  • ROE 12.0 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -2.57%
  • Company has a low return on equity of 12.3% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Allcap BSE SmallCap BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
395 396 368 302 403 348 364 401 422 445 423 455 438
353 364 350 288 374 328 348 375 388 394 375 404 394
Operating Profit 42 32 19 15 29 21 16 26 34 51 48 52 44
OPM % 11% 8% 5% 5% 7% 6% 4% 7% 8% 11% 11% 11% 10%
3 3 3 1 1 1 3 2 3 4 4 3 5
Interest -9 1 1 0 0 1 1 0 0 2 1 1 1
Depreciation 7 7 7 7 7 7 7 8 8 8 10 6 2
Profit before tax 47 27 14 8 22 14 11 21 29 44 42 48 46
Tax % 20% 21% 13% 32% 29% 36% 26% 29% 26% 27% 32% 25% 24%
37 22 12 6 16 9 8 15 21 32 29 36 35
EPS in Rs 0.83 0.48 0.26 0.11 0.31 0.18 0.16 0.29 0.42 0.63 0.55 0.71 0.64
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
326 367 401 485 595 607 769 853 1,188 1,547 1,418 1,690 1,761
295 318 352 424 534 542 701 785 1,070 1,410 1,338 1,532 1,566
Operating Profit 31 49 48 62 61 65 68 69 119 137 80 159 195
OPM % 10% 13% 12% 13% 10% 11% 9% 8% 10% 9% 6% 9% 11%
6 4 1 -3 4 4 4 9 12 10 6 14 17
Interest 12 10 9 10 8 4 2 2 2 -7 2 4 5
Depreciation 46 46 39 35 34 34 40 37 30 28 28 33 26
Profit before tax -21 -3 2 13 24 30 29 39 99 127 56 135 180
Tax % 0% 0% 6% -1% 0% 0% 1% 14% 1% 20% 31% 29%
-21 -3 2 13 24 30 29 34 97 102 39 97 132
EPS in Rs -0.46 -0.06 0.05 0.28 0.53 0.66 0.64 0.75 2.16 2.13 0.76 1.88 2.53
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 17%
5 Years: 17%
3 Years: 12%
TTM: 15%
Compounded Profit Growth
10 Years: 34%
5 Years: 27%
3 Years: 0%
TTM: 147%
Stock Price CAGR
10 Years: 22%
5 Years: 35%
3 Years: 17%
1 Year: 75%
Return on Equity
10 Years: 13%
5 Years: 15%
3 Years: 12%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 90 90 90 90 90 90 90 90 90 96 102 102 110
Reserves 90 88 78 91 106 136 163 194 291 457 651 745 1,001
231 209 201 187 169 134 132 133 17 19 25 29 33
95 103 121 156 173 226 230 246 460 499 332 417 418
Total Liabilities 506 490 489 524 538 586 615 663 858 1,070 1,110 1,293 1,562
409 368 322 297 272 264 236 216 225 252 267 307 355
CWIP 0 0 0 0 0 0 0 0 2 14 17 24 18
Investments 4 0 0 0 0 0 0 1 1 0 0 1 132
93 121 167 227 266 321 379 446 631 804 827 960 1,056
Total Assets 506 490 489 524 538 586 615 663 858 1,070 1,110 1,293 1,562

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
34 34 51 50 41 63 17 11 51 -60 -91 73
-3 -1 -32 -27 -14 -27 -13 -12 -70 -32 -47 -83
-30 -29 -19 -27 -24 -38 -0 5 47 66 144 5
Net Cash Flow 1 4 -0 -4 3 -1 4 4 28 -26 6 -5

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 44 42 51 66 57 73 64 59 56 59 68 70
Inventory Days 68 56 55 51 65 76 69 91 82 96 87 85
Days Payable 104 116 126 140 125 173 124 113 98 90 87 101
Cash Conversion Cycle 8 -17 -20 -23 -3 -24 9 37 40 65 69 54
Working Capital Days -19 -20 -18 -10 -86 -62 -30 -3 22 59 104 99
ROCE % -3% 1% 3% 8% 9% 9% 8% 10% 25% 25% 9% 17%

Shareholding Pattern

Numbers in percentages

26 Recently
Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
34.54% 38.38% 36.74% 38.22% 38.22% 38.22% 38.22% 38.22% 38.22% 38.22% 38.22% 35.66%
0.91% 0.96% 0.95% 1.15% 0.89% 0.96% 1.00% 1.29% 2.11% 1.85% 1.67% 2.08%
1.16% 1.07% 4.08% 3.98% 3.74% 2.93% 2.32% 2.27% 2.21% 2.15% 2.14% 1.69%
0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
63.39% 59.59% 58.24% 56.63% 57.15% 57.88% 58.45% 58.20% 57.46% 57.76% 57.96% 60.57%
No. of Shareholders 2,55,1552,61,4372,87,1152,90,3673,06,0303,06,1503,01,8323,04,0013,04,2893,36,0193,48,7664,30,929

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls